NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The D...
August 18 2020 - 8:00AM
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology
company focused on discovering and developing transformative
therapeutics for patients, today announced that comprehensive data
from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients
with non-alcoholic steatohepatitis (NASH) will be featured in an
oral plenary presentation at The Digital International Liver
Congress (ILC) 2020, which will be held virtually August
27-29, 2020.
Entitled “Positive topline results from a 24-week,
placebo-controlled, multicenter, paired liver biopsy study of the
FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic
steatohepatitis,” the late-breaker oral presentation (LBO-01) will
be given by Stephen A. Harrison, M.D., Medical Director at Pinnacle
Clinical Research, Visiting Professor of Hepatology at University
of Oxford, UK and principal investigator of the study, on Saturday,
August 29th at 13:00 – 13:15 CEST (7:00 – 7:15 AM ET). The
presentation will include detailed findings from the 24-week Phase
2 study as reported by NGM in February 2020, in addition to new
analyses from the study.
NGM will also have several aldafermin-related poster
presentations at Digital ILC 2020, including:
Poster
(THU-200)Abstract title:
Veillonella as a bile acid-sensitive bacteria and a
microbiome-based biomarker for aldafermin (NGM282) in patients with
non-alcoholic steatohepatitisPresenting
author: Rohit Loomba, M.D., Professor of Medicine in
the Division of Gastroenterology at University of California, San
DiegoDate and time: 8/27/2020,
9:15 – 19:30 CEST (3:15 AM – 1:30 PM ET)
Poster
(FRI-258)Abstract title:
Aldafermin (NGM282) reduces the cross-linked pro-peptides of type
III collagen PRO-C3X, a novel biomarker, in nonalcoholic
steatohepatitis and primary sclerosing cholangitis
patientsPresenting author: Stephen A.
Harrison, M.D., Medical Director of Pinnacle Clinical Research,
Visiting Professor of Hepatology at University of Oxford,
UKDate and time: 8/28/2020, 9:30 –
19:30 CEST (3:30 AM – 1:30 PM ET)
Poster
(FRI-047)Abstract title: The
FGF19 analogue aldafermin (NGM282) improves non-invasive tests
in patients with nonalcoholic steatohepatitisPresenting
author: Marno Ryan, MBBS (Hons), M.D., FRACP,
Clinical Associate Professor of Medicine, University of Melbourne,
Gastroenterologist and Hepatologist, St Vincent’s Hospital,
MelbourneDate and time: 8/28/2020,
9:30 – 19:30 CEST (3:30 AM – 1:30 PM ET)
Poster
(FRI-161)Abstract title:
Correlation of serum bile acids and pruritus
with aldafermin (NGM282) therapy in patients with primary
sclerosing cholangitisPresenting author: Lei
Ling, Ph.D., Director, Clinical Development, NGM
Biopharmaceuticals,
Inc.Date and time: 8/28/2020, 9:30
– 19:30 CEST (3:30 AM – 1:30 PM ET)
All presentations will be available to registered Digital ILC
2020 participants at the meeting website:
https://ilc-congress.eu/programme-digital-ilc-2020/.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and
developing novel therapeutics based on scientific understanding of
key biological pathways underlying liver, retinal and metabolic
diseases and cancer. We leverage our biology-centric drug discovery
approach to uncover novel mechanisms of action and generate
proprietary insights that enable us to move rapidly
into proof-of-concept studies and deliver
potential first-in-class medicines to patients. At NGM,
we aspire to operate one of the most productive research and
development engines in the biopharmaceutical industry, with
multiple programs in clinical development. Visit us
at www.ngmbio.com for more information.
Investor
Contact:Alex Schwartzir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Sep 2023 to Sep 2024